Keywords: S*BIO, Onyx, JAK2 inhibitor, Almirall, Nycomed, Roflumilast, Daxas
S*BIO regains rights from Onyx for JAK2 inhibitor program; Almirall to market co-brand of Nycomed’s roflumilast in Spain
Article | 05 May 2011
Privately-held Singapore-headquartered biotech firm S*BIO Pte has announced the restructuring of its collaboration and option agreement with US drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
